<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02323737</url>
  </required_header>
  <id_info>
    <org_study_id>CH-L-022</org_study_id>
    <nct_id>NCT02323737</nct_id>
  </id_info>
  <brief_title>Phase II Study of Irinotecan and Cisplatin in Extensive-stage Small Cell Lung Cancer</brief_title>
  <official_title>Cisplatin Combined With Irinotecan or Etoposide for Untreated Extensive-stage Small Cell Lung Cancer: a Multicenter Randomized Control Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>China-Japan Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with untreated extensive-stage small cell lung cancer(SCLC) were randomly assigned
      to receive either irinotecan/cisplatin (IP) or etoposide/cisplatin(EP), The association of
      efficacy and toxicity of IP regimen was analyzed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, multicenter study. Patients are randomized to irinotecan/cisplatin (IP)
      or etoposide/cisplatin (EP) treatment arms. The IP regimen consisted of at most 6 cycles of
      irinotecan 65 mg/m2 of body-surface area on days 1, 8 and cisplatin 75mg/m2 of body-surface
      area on day 1. The EP regimen consisted of at most 6 cycles of etoposide 100 mg/m2 of
      body-surface area from day 1 to 3 and cisplatin 75mg/m2 of body-surface area on day 1. Cycle
      length for the two arms was 3 weeks. The dose adjustment was allowed in at most within Â±5%
      per investigator discretion if necessary.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Extensive-stage Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Irinotecan and cisplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The IP regimen consisted of at most 6 cycles of irinotecan 65 mg/m2 of body-surface area on days 1, 8 and cisplatin 75mg/m2 of body-surface area on day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Etoposide and Cisplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The EP regimen consisted of at most 6 cycles of etoposide 100 mg/m2 of body-surface area from day 1 to 3 and cisplatin 75mg/m2 of body-surface area on day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan and cisplatin</intervention_name>
    <arm_group_label>Irinotecan and cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide and cisplatin</intervention_name>
    <arm_group_label>Etoposide and Cisplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eastern Cooperative Oncology Group (ECOG) of 0 to 2

          -  A life expectancy of at least 3 months

          -  Measurable lesions

          -  Adequate hematologic function

        Exclusion Criteria:

          -  Infection

          -  Myocardial infarction within the preceding three months

          -  Symptomatic brain metastases or receiving radiotherapy less than 4 weeks

          -  Pregnancy or breast-feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>yuankai shi, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Institute/Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College</affiliation>
  </overall_official>
  <overall_official>
    <last_name>xingsheng Hu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Institute/Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Institute/Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2014</study_first_submitted>
  <study_first_submitted_qc>December 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2014</study_first_posted>
  <last_update_submitted>December 29, 2014</last_update_submitted>
  <last_update_submitted_qc>December 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Shi Yuankai</investigator_full_name>
    <investigator_title>Cancer Institute/Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

